Kanion Pharmaceutical: Wholly-owned subsidiary's drug receives approval for additional indications

Zhitong
2025.10.29 09:55

Kanion Pharmaceutical announced that its wholly-owned subsidiary Jiangsu Zhongxin Pharmaceutical Co., Ltd. recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration regarding the new indication for ZX2021 injection for the treatment of metabolic dysfunction-related fatty liver disease

Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer